Search results
Showing 1 to 15 of 32 results for daratumumab
Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA783)
Evidence-based recommendations on daratumumab (Darzalex) for relapsed and refractory multiple myeloma in adults.
Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (TA897)
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, thalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable.
Evidence-based recommendations on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma in adults, when a stem cell transplant is unsuitable.
NICE is unable to make a recommendation on daratumumab (Darzalex) with lenalidomide and dexamethasone for untreated multiple myeloma, because Janssen did not provide an evidence submission.
Show all sections
Sections for TA634
NICE is unable to make a recommendation on daratumumab (Darzalex) with bortezomib, melphalan and prednisone for untreated multiple myeloma because Janssen did not provide an evidence submission.
Show all sections
Sections for TA771
NICE is unable to make a recommendation on daratumumab (Darzalex) with pomalidomide (Imnovid) and dexamethasone for treating relapsed or refractory multiple myeloma because Janssen did not provide an evidence submission.
Show all sections
Sections for TA726
NICE is unable to make a recommendation on carfilzomib (Kyprolis) with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma in adults. This is because Amgen did not provide an evidence submission.
Show all sections
Sections for TA841
NICE is unable to make a recommendation about the use in the NHS of daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma because no evidence submission was received from Janssen-Cilag.
Show all sections
Sections for TA454
In development [GID-TA11254] Expected publication date: TBC
In development [GID-TA10726] Expected publication date: TBC
Evidence-based recommendations on isatuximab (Sarclisa) with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma in adults.
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma (TA695)
Evidence-based recommendations on carfilzomib (Kyprolis) with dexamethasone and lenalidomide (Revlimid) for previously treated multiple myeloma in adults.